News & Events
HR Wins Department of the Year Award
Congratulations to the Department of Human Resources for winning the annual HR Department of the Year Award! Presented by the Delaware Valley HR Executive Alliance group, more than 450 HR executives gathered in the Crystal Tea Room on November 20, 2014, in anticipation to find out who won in various categories and for overall best department.
New Approach for Treating ALS
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, is a neurodegenerative disease that primarily kills motor neurons, leading to paralysis and death 2 to 5 years from diagnosis. Currently ALS has no cure. Despite promising early-stage research, the majority of drugs in development for ALS have failed. Now researchers have uncovered a possible explanation. In a study published November 20th in the Annals of Clinical and Translational Neurology, researchers show that the brain’s machinery for pumping out toxins is ratcheted up in ALS patients and that this machinery also pumps out medicine designed to treat ALS, thereby decreasing the therapeutic efficacy of the drug.
Fat a Culprit in Fibrotic Lung Damage
Pulmonary fibrosis has no cure. It’s caused by scarring that seems to feed on itself, with the tougher, less elastic tissue replacing the ever moving and stretching lung, making it increasingly difficult for patients to breathe. Researchers debate whether the lung tissue is directly damaged, or whether immune cells initiate the scarring process – an important distinction when trying to find new ways to battle the disease. Now research shows that both processes may be important, and suggest a new direction for developing novel therapies.
Killing Cancer by Protecting Normal Cells
Although radiation treatments have become much more refined in recent years, it remains a challenge to both sufficiently dose the tumor while sparing the surrounding tissue.
Novel Cancer Vaccine Approach for Brain Tumors
Glioblastoma is the most common aggressive primary brain tumor, and despite advances in standard treatment, the median survival is about 15 months (compared to 4 months without treatment). Researchers at Thomas Jefferson University have been working on a cancer vaccine that would extend that survival by activating the patient’s immune system to fight the brain tumor.
Fighting for Cancer Patients
Abington Health & Jefferson: Reimagining Region’s Health Care
The chief executives of Abington Health and Jefferson announced today that their respective Boards of Trustees have voted to enter into a Letter of Intent and to move forward with a framework for merging the two organizations.
Hormone Loss Could be Involved in Colon Cancer
Some cancers, like breast and prostate cancer, are driven by hormones such as estrogen and testosterone, but to date, there are none that are driven by the lack of a hormone.
Ideas for Innovating Health Care:
Society of Physician Entrepreneurs Event October 25th
All physicians and healthcare providers are welcome to attend the meeting, which features Jeff Joseph, DO, Professor of Anesthesiology at the Sidney Kimmel Medical College at Thomas Jefferson University as one of the speakers. Take part in networking and the Q&A session. The free event is 9 a.m. to 10:30 a.m. in 207 Jefferson Alumni Hall.
New Target for Treatment of Multiple Sclerosis?
A study published in the October, 2014 issue of Nature Medicine points to a new target for the treatment of multiple sclerosis (M.S.).